Eliquis Dosing with Paxlovid

Mechanism of Interaction

Ritonavir, a component of Paxlovid, is a potent CYP3A4 inhibitor that significantly increases apixaban plasma concentrations, as CYP3A4 is a major metabolic pathway for apixaban, according to the British Medical Journal 1, 2
The ritonavir component causes drug-drug interactions during active treatment and for several days after completion, as reported in the British Medical Journal 1, 2

During Paxlovid treatment, maintain the twice-daily dosing schedule approximately 12 hours apart, as recommended by Praxis Medical Insights 3

Monitor patients for bleeding signs, including unusual bruising and gastrointestinal bleeding, as advised by Praxis Medical Insights 3
Watch for common Paxlovid adverse effects such as dysgeusia and diarrhea, which do not require discontinuation, according to the British Medical Journal and Praxis Medical Insights 1, 2, 4
Monitor renal function during treatment, as COVID-19 itself can cause acute kidney injury, which would further increase apixaban levels, as noted by Praxis Medical Insights 4

For patients with renal impairment (creatinine clearance 30-59 mL/min), reduce Paxlovid dose to 150 mg/100 mg nirmatrelvir/ritonavir twice daily, as recommended by the British Medical Journal and Praxis Medical Insights 1, 2, 4
Apixaban dose reduction may need further adjustment based on renal function independent of the drug interaction, according to Praxis Medical Insights 3
Use Paxlovid with caution in severe liver impairment, as trials excluded these patients, as reported in the British Medical Journal and Praxis Medical Insights 1, 2, 4

Do not add antiplatelet agents during this period unless absolutely necessary for acute vascular disease, as this compounds bleeding risk, as advised by Praxis Medical Insights 3, 5
Do not use the Liverpool COVID-19 Drug Interaction Tool as optional, as this is explicitly recommended in guidelines for systematic interaction checking, according to the British Medical Journal and Praxis Medical Insights 1, 2, 4
Do not delay Paxlovid initiation due to anticoagulation concerns; the interaction is manageable with dose adjustment, and Paxlovid must be started within 5 days of symptom onset for effectiveness, as reported in the British Medical Journal and Praxis Medical Insights 1, 2, 4